ArticleNPJ Parkinson's disease2024
Uric acid and alterations of purine recycling disorders in Parkinson's disease: a cross-sectional study.
Article in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07170475 (A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease
Who cites it
10 citing papers in PubMed.
- A novel oxidative-inflammatory biomarker for Parkinson's disease: clinical utility of the uric acid-to-albumin ratio.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Plasma LC-HRMS metabolomics in parkinsonian syndromes: comparative evaluation of sample preparation protocols for exploratory metabolic signatures.Analytical and bioanalytical chemistry · 2026Article
- Adenosine Deaminase-Mediated Purine Dysfunction Leads to DNA Repair Inhibition and Senescence in Sporadic Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2026Article
- Peripheral immunochemical considerations in Parkinson disease: sources, targets and crosstalk mechanisms.Journal of translational medicine · 2026Review
- Lower serum uric acid levels as a risk factor for depression in prodromal Parkinson's disease: a cohort study.Open life sciences · 2026Article
- Classification of Parkinson's disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome.NPJ Parkinson's disease · 2025Article
- Review
- Association between RC/HDL-C and hyperuricemia in adults: evidence from NHANES 2005-2018.Frontiers in endocrinology · 2025Article
- Brain network and energy imbalance in Parkinson's disease: linking ATP reduction andFrontiers in molecular neuroscience · 2024Review
- Discovery of a preliminary urinary metabolite panel for Parkinson's disease: a pilot study using paired patient-spouse samples and machine learning consensus.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The relationship between reduced serum uric acid (UA) levels and Parkinson's disease (PD), particularly purine metabolic pathways, is not fully understood. Our study compared serum and cerebrospinal fluid (CSF) levels of inosine, hypoxanthine, xanthine, and UA in PD patients and healthy controls. We analyzed 132 samples (serum, 45 PD, and 29 age- and sex-matched healthy controls; CSF, 39 PD, and 19 age- and sex-matched healthy controls) using liquid chromatography-tandem mass spectrometry. Results showed significantly lower serum and CSF UA levels in PD patients than in controls (p < 0.0001; effect size r = 0.5007 in serum, p = 0.0046; r = 0.3720 in CSF). Decreased serum hypoxanthine levels were observed (p = 0.0002; r = 0.4338) in PD patients compared to controls with decreased CSF inosine and hypoxanthine levels (p < 0.0001, r = 0.5396: p = 0.0276, r = 0.2893). A general linear model analysis indicated that the reduced UA levels were mainly due to external factors such as sex and weight in serum and age and weight in CSF unrelated to the purine metabolic pathway. Our findings highlight that decreased UA levels in PD are influenced by factors beyond purine metabolism, including external factors such as sex, weight, and age, emphasizing the need for further research into the underlying mechanisms and potential therapeutic approaches.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.